Samsung Bioepis Responds To Rumor Of Biogen Biosimilars Buyout

Korean Media Suggests Former Partner Could Acquire Remaining Biosimilars Business

 
• By David Wallace
  
Deal - Yes or No? Spelled out on cubes
Samsung Bioepis is rumored to be considering a bid for Biogen’s biosimilars business • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business